How I manage CAR-T therapies and bispecific antibodies for my patients: GOING VIRTUAL

 

How I Manage
CAR-T Therapies and Bispecific Antibodies
for my Patients

 

New dates: September 6-9, 2021
GOING VIRTUAL

 

Chairs: Peter Borchmann, Ulrich Jäger, Marie José Kersten

---

CALL FOR ABSTRACTS AND CLINICAL CASES!
DEADLINE: JUNE 6, 2021

 

---

ABOUT THE CONFERENCE

In view of continuing COVID-19 related challenges, the ESH “How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients” conference will be held as a virtual event.

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

About the programme:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies.
The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.
The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.
In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, authorities and industry.

Learning objectives:
Upon completion of this CME activity, participants should have improved understanding of:
1.  the current landscape of CAR-T cells and bispecific antibodies
2.  novel approaches and technologies in the field
3.  how to integrate these novel therapies into current clinical practice
4.  future perspectives in bispecific antibody and cellular therapies in haematological malignancies and solid tumours.

STAY TUNED REGISTRATION OPENING SOON
TO ACCESS THE PROGRAMME CLICK HERE
MORE INFORMATION